Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 21 August 2026, providing investors with an up-to-date view of the company’s standing in the market.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended June 2026, signalling a pause in its recent negative trend. Despite achieving record quarterly sales and profitability metrics, the company continues to face challenges in profitability growth and cash reserves, reflecting a complex financial landscape for investors to navigate.

Balaxi Pharmaceuticals Ltd. reported a net profit of ₹1.30 crores for Q1 FY27, representing a substantial sequential improvement of 113.11% from ₹0.61 crores in Q4 FY26 and a dramatic year-on-year surge of 348.28% from ₹0.29 crores in Q1 FY26. The micro-cap pharmaceutical company, with a market capitalisation of ₹136.00 crores, delivered revenue of ₹80.68 crores for the quarter, marking a 14.10% sequential growth and 14.05% year-on-year expansion.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 30 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 19 July 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 08 July 2026, providing investors with the latest perspective on the company’s position.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 27 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 16 June 2026, providing investors with the latest insights into its performance and outlook.

At Rs 23.99, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Balaxi Pharmaceuticals Ltd locked at its upper circuit of 4.81% on 15 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant shift in its valuation parameters, moving from a previously attractive valuation to being classified as very expensive. This transformation is underscored by a sharp rise in its price-to-earnings (P/E) ratio and a contrastingly low price-to-book value (P/BV), raising questions about the stock’s price attractiveness relative to its historical and peer benchmarks.

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 June 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended March 2026. The company’s recent quarterly results reveal a marked contraction in revenue and profitability, signalling a shift from a previously flat financial trend to a distinctly negative trajectory.

Balaxi Pharmaceuticals Ltd. has reported deeply concerning Q4 FY26 results that reveal severe operational deterioration, with net profit collapsing 92.94% year-on-year to just ₹0.61 crores despite a ₹141.00 crore market capitalisation. The micro-cap pharmaceutical company's operating margin has virtually evaporated to a mere 0.17%, down from 16.47% in the same quarter last year, whilst revenue declined 7.29% to ₹70.71 crores. The stock has responded brutally to the company's sustained underperformance, plummeting 47.55% over the past year and trading 58.98% below its 52-week high of ₹63.90.

At Rs 24.11, sellers were still queuing — but there were no buyers willing to take the other side. Balaxi Pharmaceuticals Ltd locked at its lower circuit of 5% on 27 May 2026, with unfilled sell orders and a frozen price.